The Global Sepsis Diagnostics Market to Register Growth at

New York, USA, Oct. 06, 2022 (GLOBE NEWSWIRE) — The Global Sepsis Diagnostics Market to Register Growth at a CAGR of 9.60% by 2027 | DelveInsight

The sepsis diagnostics market is expanding due to factors such as the rising prevalence of the COVID-19 pandemic, an increase in the geriatric population, an increase in the prevalence of bacterial infections such as tuberculosis, and an increase in regulatory approvals for technologically advanced sepsis diagnostics products. As a result, the sepsis diagnostics market is expected to grow at a significant CAGR from 2022 to 2027.

DelveInsight’s Sepsis Diagnostics Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, sepsis diagnostics market drivers, barriers, and trends, and key sepsis diagnostics companies in the market. 

Key Takeaways from the Sepsis Diagnostics Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global sepsis diagnostics market during the forecast period. 
• Notable sepsis diagnostics companies such as BD, Cytovale™ Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMérieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and several others are currently operating in the sepsis diagnostics market.
• In January 2022, Pathogenomix, a next-generation sequencing pathogen diagnostic company, was granted US Food and Drug Administration (FDA) Breakthrough Device Designation for its Patho-Seq assay. The assay is designed to quickly detect and identify hundreds of clinically important bacteria for a wide range of clinical diseases and sample types, including sepsis from whole blood samples and…